The randomized PACIFIC study demonstrates that treatment of stage III NSCLC patients, who do not have disease progression after platinum-based chemoradiotherapy, with anti-PD-L1 antibody durvalumab improves the overall survival [271]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.